Table 4 Univariate analysis of factors affecting RFS of patients with adjuvant therapy
Clinico-pathological feature | Chemotherapy | Endocrine therapy |
|---|---|---|
p value (HR;CI) | p value (HR;CI) | |
Age (≤35, 36–60, > 60 years) | 0.598 (0.919; 0.670–1.260) | 0.979 (1.011; 0.463–2.205) |
Nottingham grade | 0.052 (1.290; 0.998–1.668) | 0.010 (2.355; 1.225–4.526) |
Tumour size (< 2, 2–5, > 5 cm) | 0.109 (1.249; 0.952–1.640) | 0.320 (1.413; 0.713–2.806) |
Presence or absence of lymph node metastasis | 0.002 (0.575; 0.408–0.809) | 0.467 (0.739; 0.327–1.669) |
Lymph node stage | < 0.001 (1.370; 1.183–1.587) | 0.096 (1.370; 0.946–1.984) |
TNM stage | < 0.001 (1.792; 1.399–2.296) | 0.036 (1.884; 1.041–3.408) |
Lympho-vascular invasion | 0.061 (0.856; 0.727–1.007) | 0.014 (0.604; 0.404–0.902) |
ER expression | 0.031 (1.468; 1.036–2.079) | – |
PgR expression | 0.007 (1.608; 1.137–2.274) | – |
HER2 over-expression | 0.016 (0.789; 0.651–0.956) | 0.003 (0.484; 0.302–0.777) |
KIBRA – 4 groups | 0.231 (1.098; 0.942–1.279) | 0.166 (1.279; 0.903–1.813) |
KIBRA-low | 0.019 (0.649; 0.451–0.932) | 0.025 (0.389; 0.170–0.890) |
Molecular subtype | 0.078 (1.092; 0.990–1.203) | 0.063 (1.489; 0.979–2.264) |
Ki 67 ≥ 14% cells | 0.546 (0.875; 0.566–1.351) | 0.245 (0.558; 0.209–1.492) |